1.Myasthenia Gravis Treatment Updates.Curr Treat Options Neurol. (2020) 22:24. 2. 俞海,蒋雨平.重症肌无力的治疗[J].中国临床神经科学,2018,26(06):658-668+675. 3. 中国重症肌无力诊断和治疗指南(2020版). 中国神经免疫学和神经病学杂志.202...
[6]Zhang Z, Wang Z, Du X, et al. Refractory generalized myasthenia gravis treated successfully with telitacicept: two cases report[J]. J Neurol, 2024,271(1):584-588. [7]Zhang C, Lin Y, Kuang Q, et al. Case report: A highly active refractory myasthenia gravis with treatment of tel...
We performed ten plasma perfusion (PP) treatments on eight patients affected by Myasthenia Gravis (MG) with high serum levels of autoantibodies against acetylcholine receptors (anti AChR-AB), and one PP treatment on a patient with MG of probable genetic origin and without specific antibodies. All...
重症肌无力(Myasthenia Gravis,MG)是一种影响神经与肌肉之间信号传递的自身免疫性疾病。MG的发病机制涉及自身抗体攻击神经肌肉接头(NMJ),这是神经细胞与肌肉细胞之间传递信号的地方。两种主要责任抗体是致病性乙酰胆碱受体(AChR)抗体和肌肉特异性酪氨酸激酶(MuSK)抗体。该疾病可累及全身骨骼肌,临床特点为波动性无力和病理...
[7]Zhang C, Lin Y, Kuang Q, et al. Case report: A highly active refractory myasthenia gravis with treatment of telitacicept combined with efgartigimod[J]. Front Immunol, 2024,15:1400459. 仅供医学人士参考
What to Expect with Long-Term Myasthenia Gravis Treatment Get tips for sticking to a routine, effective doctor communication and more. 7 MIN READ TRACKING SYMPTOMS Managing Your MG Symptoms: Limb Weakness Learn from experts and others living with MG how to address limb weakness symptoms and he...
myasthenia gravis patients like you manage their symptoms Share your experience in a 3 minute survey Get instant access to the full report You have the option to share more information and get access to detailed insights over timeGet my insights Learn what myasthenia gravis patients say about thei...
1.Morren JA, Li Y. Myasthenia gravis: Frequently asked questions. Cleve Clin J Med. 2023 Feb 1;90(2):103-113. 2.Zust C, Morren JA. What are the treatment options for myasthenia gravis if first-line agents fail? Cleve Clin J Med. 2023 Feb 1;90(2):81-84. ...
5.Sivadasan A, Bril V. Clinical efficacy and safety of efgartigimod for treatment of myasthenia gravis.[Z]. 2023: 15, 553-563. 6.Bril V, Drużdż A, et al. Safety and efficacy of rozanolixizumab in patients wit...
[7]Zhang C, Lin Y, Kuang Q, et al. Case report: A highly active refractory myasthenia gravis with treatment of telitacicept combined with efgartigimod[J]. Front Immunol, 2024,15:1400459.